HCW Biologics Inc. (NASDAQ: HCWB) has requested a Type B pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the development and regulatory strategy for its lead product candidate, HCW11-018b. The Miramar-based clinical-stage biopharmaceutical company announced on July 23, 2026, that it remains on track to initiate clinical trials for the compound in the first half of 2027. This engagement marks a critical step in advancing the proprietary tetravalent T-cell engager (TCE) program toward human testing, addressing significant unmet needs in solid tumor treatment where immunosuppression often limits therapeutic efficacy.

The proposed meeting will cover clinical trial designs, nonclinical testing programs, and Chemistry, Manufacturing, and Controls (CMC) data. HCW Biologics intends to use the engagement to align with the FDA on the path forward for HCW11-018b, which is constructed using the company’s proprietary TRBC drug development platform. Unlike first-generation TCEs that face challenges with antigen selection, tolerability, and complex manufacturing, HCW11-018b is designed to overcome these limitations through its unique structural composition.

Mechanism of Action and Preclinical Data

HCW11-018b is administered via subcutaneous injection and targets tissue factor-expressing cancer cells while activating CD3-positive effector T cells. The molecule combines a tumor-associated tissue factor-targeting BiTE with IL-15 immune stimulation and a TGF-β trap to reduce immunosuppression in the tumor microenvironment. This "Big BiTE" structure avoids Fc fusion technology, relying instead on the TRBC platform to induce robust, antigen-specific tumor killing.

Preclinical studies indicate that HCW11-018b enhances CD8⁺ T-cell activation, survival, and effector functions. Crucially, the data shows the compound does not trigger cytokine release syndrome within its therapeutic dose range, a major safety concern associated with earlier BiTE therapies. The candidate has demonstrated potent anti-pancreatic cancer activities in both in vitro settings and humanized mouse models.

Manufacturing and Commercial Strategy

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, highlighted the development of a streamlined, cost-efficient manufacturing process for HCW11-018b. The process utilizes high-producing recombinant CHO cell lines and a proprietary monoclonal antibody for affinity purification. The monoclonal antibody is currently being manufactured under GMP standards by a top-tier Contract Development and Manufacturing Organization (CDMO). This approach is designed to produce high-quality cGMP material at a lower cost than current methods, supporting both clinical development and potential future commercialization.

Market Context and Outlook

The TCE therapeutic modality has seen growing interest, with the U.S. FDA and other agencies approving eight TCEs for 12 indications to date. Despite limited approvals, these therapies generate multi-billion-dollar annual sales, driving high-value partnerships between major pharmaceutical companies and innovative biotechs. HCW Biologics positions HCW11-018b as a second-generation solution capable of penetrating the tumor microenvironment effectively, particularly in cancers such as pancreatic and gynecologic tumors where immunosuppression is a barrier to treatment.

What the Numbers Show

The strategic focus on manufacturing efficiency alongside clinical advancement signals an attempt to de-risk the commercial viability of HCW11-018b early in its development cycle. By establishing a cost-efficient cGMP production method now, HCW Biologics aims to mitigate the supply chain and cost barriers that have historically plagued complex fusion immunotherapeutics. The absence of cytokine release syndrome in preclinical models further differentiates the candidate, potentially reducing trial-related adverse events and improving patient tolerability compared to first-generation TCEs.

HCW Biologics Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, on June 29, 2026, following a decision by the Nasdaq Hearings Panel. To ensure long-term adherence to the rule, the company executed a 1-for-6 reverse stock split effective June 30, 2026. The company is subject to a mandatory monitoring period through June 17, 2027.

Reverse Split and Trading Details

The reverse stock split reduced the number of issued and outstanding shares from 9,581,079 to approximately 1,596,849. The company’s common stock began trading on a reverse split-adjusted basis on The Nasdaq Capital Market under the symbol "HCWB." The total authorized shares remain at 250,000,000, and the par value stays at $0.0001 per share. Equiniti Trust Company LLC serves as the exchange agent.

Compliance Timeline

The Nasdaq Hearings Panel had previously ruled on May 29, 2026, requiring the stock to trade above $1.00 per share for at least 20 days prior to July 29, 2026. HCW Biologics met this threshold on June 12, 2026. The company filed amendments to its Certificate of Incorporation with the Delaware Secretary of State on June 24, 2026, to effect the split. The new CUSIP number for the common stock is 40423R303.

Shareholder Impact

The reverse stock split affects all stockholders uniformly without altering percentage ownership interests, except for fractional shares. No fractional shares will be issued; stockholders otherwise entitled to a fraction will receive one whole share. Shares available for issuance under equity incentive plans and those issuable upon the exercise of outstanding stock options and warrants will be proportionately adjusted. Exercise prices for outstanding options and warrants will also be modified.